← Back to contracts

Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients

US National Cancer Institute grant open #nih-5R01CA255479-05

Summary

7. Project Summary/Abstract Gliomas are rarely curable tumors with a low survival rate of 36% at five-years that is well below the average survival rate of 67.2% across all cancers, according to SEER and CBTRUS. Malignant brain tumors cause an average of 20 years of potential life lost (YPLL) for individuals diagnosed as adults, which exceeds most common cancers. Survival and YPLL have not improved for gliomas similarly to other cancers and progress is desperately needed. The lack of improvement in patient outcomes is not due to lack of new discoveries, but due to limited success in translatin

Development of next generation 2HG and met…
Onboard